Skip to content
| Target | Drug Name | Code | Approved Time | Company | Partner |
| PD-1 mAb | Toripalimab | JS001 | 2018-12 | Junshi | LO: Coherus |
| PD-1 mAb | Sintilimab | IBI308 | 2018-12 | Innovent | LO: Eli Lilly |
| PD-1 mAb | Camrelizumab | SHR-121 | 2019-05 | Hengrui | |
| PD-1 mAb | Tislelizumab | | 2019-12 | BeOne | LO: |
| PD-1 mAb | Penpulimab | AK105 | 2021-08 | Akeso | CTTQ |
| PD-1 mAb | | HX008 | 2022-07 | Lepu | |
| | | | | |
| PD-L1 mAb | Adebrelimab | | 2023-02 | Hengrui | |
| | | | | |
| PD-1/CTLA-4 BsAb | Candonilimab | | 2022 | Akeso | |
| CD20 mAB | Zuberitamab | | 2023-05 | | |
| HER2 ADC | Disitamab Vedotin | RC48 | 2021-06 | RameGen | LO: Seagen |
| HER2 ADC | Trastuzumab Rezetecan | SHR-A1811 | 2025-05 | Hengrui | |
| | | | | |
| TROP2 ADC | Sacituzumab Tirumotecan | | 2024-11 | Kelun | |
| | | | | |
| VEGF-A/PD-1 BsAb | Ivonescimab | | 2024 | Akeso | |
| | | | | |
| IL-4Rα | Stapokibart | | | Kangnuoxing | |
| | | | | |
| IL-17A mAb | Vunakizumab | | 2025 | Suncadia | |
